This guidance document focuses on the diagnosis and treatment of venous
thromboembolism (VTE). Efficient, cost effective diagnosis of VTE is facilitated by combining …

Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent)
venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a …

Background Specific reversal agents for non–vitamin K antagonist oral anticoagulants are
lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant …

Venous thromboembolism is a very common and costly health problem worldwide.
Anticoagulant treatment for VTE is imperfect: all have the potential for significant bleeding …

Deep venous thrombosis (DVT) is part of a spectrum of venous thromboembolic disorders
that includes superficial thrombophlebitis and pulmonary embolism. 1 DVT may be defined …

Direct oral anticoagulant therapies, including direct anti-Xa and thrombin inhibitors have
recently been introduced and may have advantages over vitamin K antagonists such as …

The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which
inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit …

Chronic oral anticoagulation frequently requires interruption for various reasons and
durations. Whether or not to bridge with heparin or other anticoagulants is a common clinical …

Thrombin-mediated proteolysis is a major determinant of metastasis, but is not universally
important for primary tumor growth. Here, we report that colorectal adenocarcinoma …

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and
pulmonary embolism, is a common cardiovascular disease associated with significant …